Although the prognostic value of plasma biomarkers in patients with symptomatic AD has been somewhat less well studied, several investigations suggest that plasma neurofilament light (NfL), a marker of axonal damage, may hold particular promise for predicting and tracking changes in patients with mild cognitive impairment (MCI) or dementia due to AD [9, 10]. This evidence concerns the gene NEFL and Cognitive impairment.